A second chance at prevention: could provider training shield cancer survivors from HPV-Related cancers?

NCT ID NCT04469569

Completed Prevention Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether a program that trains pediatric oncology providers—called HPV-PROTECT—can increase HPV vaccination among young cancer survivors aged 9 to 17 who are at least one year past treatment. These survivors face a higher risk of new cancers caused by HPV, yet vaccination rates are low. The program includes communication training, peer feedback, and a toolkit to help providers make strong vaccine recommendations. The study will compare clinics using the program to those providing usual care, measuring how many survivors start the HPV vaccine series.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPV-PROTECT, a provider-focused behavioral intervention including communication training, peer feedback, and a toolkit
What this could lead to: If effective, this approach could increase HPV vaccination among young cancer survivors, potentially preventing HPV-related cancers in this high-risk group.
What could go wrong: The trial's success depends on provider behavior change and may not generalize beyond participating clinics. Vaccine uptake could remain low due to other barriers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAPILLOMAVIRUS VACCINES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAPILLOMAVIRUS VACCINES

Contacts and locations

Locations

Baylor College of Medicine

Houston, Texas, 77030-3411, United States
Emory University

Atlanta, Georgia, 30322, United States
Oregon Health and Science University

Portland, Oregon, 97239-3098, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
University of Minnesota

Minneapolis, Minnesota, 55455-0341, United States
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.